Lynn Anne Bristol

Array ( [id] => 16297814 [patent_doc_number] => 20200283537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => COMPOSITIONS AND METHODS FOR MAKING AND USING BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/764331 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16764331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16297814 [patent_doc_number] => 20200283537 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => COMPOSITIONS AND METHODS FOR MAKING AND USING BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/764331 [patent_app_country] => US [patent_app_date] => 2018-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16764331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14439125 [patent_doc_number] => 20190177435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS [patent_app_type] => utility [patent_app_number] => 16/184203 [patent_app_country] => US [patent_app_date] => 2018-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16184203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14375215 [patent_doc_number] => 20190161520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => MSA2 AFFINITY-ENHANCED BIOTIN-BINDING CHIMERIC ANTIGEN RECEPTOR (CAR) [patent_app_type] => utility [patent_app_number] => 16/183579 [patent_app_country] => US [patent_app_date] => 2018-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16183579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293663 [patent_doc_number] => 20190389967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => METHOD OF TREATING AND DIAGNOSING ALPHA-V-BETA-6 OVEREXPRESSING CANCER [patent_app_type] => utility [patent_app_number] => 16/181907 [patent_app_country] => US [patent_app_date] => 2018-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16181907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14897011 [patent_doc_number] => 20190292271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/181054 [patent_app_country] => US [patent_app_date] => 2018-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16181054 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14375281 [patent_doc_number] => 20190161553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 16/178571 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 136688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16178571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17526880 [patent_doc_number] => 11299552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-12 [patent_title] => Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy [patent_app_type] => utility [patent_app_number] => 16/177740 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 22 [patent_no_of_words] => 10757 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 174 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16177740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16755350 [patent_doc_number] => 10973878 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Recombinant fusion protein containing an anti-PD-L1 antibody [patent_app_type] => utility [patent_app_number] => 16/170024 [patent_app_country] => US [patent_app_date] => 2018-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 8110 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915880 [patent_doc_number] => 20210188972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => MONOCLONAL ANTIBODIES AND CONJUGATES AGAINST PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/755685 [patent_app_country] => US [patent_app_date] => 2018-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16253546 [patent_doc_number] => 20200262920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-20 [patent_title] => DOSING REGIMEN FOR CD3 BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 16/755426 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28865 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14213949 [patent_doc_number] => 20190119359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => Novel Antibody Frameworks [patent_app_type] => utility [patent_app_number] => 16/156036 [patent_app_country] => US [patent_app_date] => 2018-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 361 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16156036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16878050 [patent_doc_number] => 11028183 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => HER2/neu-specific antibodies and methods of using same [patent_app_type] => utility [patent_app_number] => 16/156382 [patent_app_country] => US [patent_app_date] => 2018-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 13 [patent_no_of_words] => 29238 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16156382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072405 [patent_doc_number] => 20190085090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => CROSS-LINKING POLYPEPTIDE THAT INDUCES APOPTOSIS [patent_app_type] => utility [patent_app_number] => 16/151623 [patent_app_country] => US [patent_app_date] => 2018-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16151623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16268858 [patent_doc_number] => 20200270345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => Antibodies specific to CD47 and PD-L1 [patent_app_type] => utility [patent_app_number] => 16/753587 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925487 [patent_doc_number] => 11046951 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Surface display of whole antibodies in eukaryotes [patent_app_type] => utility [patent_app_number] => 16/150674 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 23 [patent_no_of_words] => 27816 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 409 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16150674 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840593 [patent_doc_number] => 20190023781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => THERAPEUTIC DRUG FOR MALIGNANT TUMORS [patent_app_type] => utility [patent_app_number] => 16/151232 [patent_app_country] => US [patent_app_date] => 2018-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16151232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713502 [patent_doc_number] => 11377485 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Methods for modifying human antibodies by glycan engineering [patent_app_type] => utility [patent_app_number] => 16/150164 [patent_app_country] => US [patent_app_date] => 2018-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 10 [patent_no_of_words] => 26158 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16150164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17453025 [patent_doc_number] => 11267870 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Methods for modifying human antibodies by glycan engineering [patent_app_type] => utility [patent_app_number] => 16/150190 [patent_app_country] => US [patent_app_date] => 2018-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 11684 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16150190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14578485 [patent_doc_number] => 20190216851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => Modified Cell Expansion and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/146218 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16146218 [rel_patent_id] =>[rel_patent_doc_number] =>)